MTAP and lung carcinoma: The prevalence of homozygous MTAP‐CDKN2A loss in our small lung cancer cohort was 12.2%, comparable with the reported range of 7.6%–13.4% in the literature [28, 29, 30], but a larger sample size is required for a more accurate analysis.